Clicky

Arrowhead Pharmaceuticals Inc(HDP1)

Description: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.


Keywords: Liver Disease Amyotrophic Lateral Sclerosis Idiopathic Pulmonary Fibrosis Dyslipidemia Antitrypsin Deficiency Renal Diseases Hypertriglyceridemia Facioscapulohumeral Muscular Dystrophy Mixed Dyslipidemia Arrowhead Pharmaceuticals Intractable Diseases Treatment For Liver Disease Treatment Of Intractable Diseases

Home Page: arrowheadpharma.com

177 East Colorado Boulevard
Pasadena, CA 91105
United States
Phone: 626 304 3400


Officers

Name Title
Dr. Christopher R. Anzalone Ph.D. CEO, President & Director
Mr. Kenneth A. Myszkowski CPA, CPA, MBA Chief Financial Officer
Mr. Patrick O'Brien J.D., PharmD COO, General Counsel & Secretary
Dr. James C. Hamilton M.D., MBA Chief of Discovery & Translational Medicine
Dr. Mark M. Davis Ph.D. Founder and Founder & Director of Insert Therapeutics Inc & Calando
Dr. Vincent Anzalone CFA Head of Investor Relations & VP
Mr. Howard Lovy Director of Communications
Dr. Bruce D. Given M.D. Chief Medical Scientist
Dr. Mark Seefeld Head of Toxicology & VP
Aaron Tan Head of Tax

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 111.1111
Trailing PE: 0
Price-to-Book MRQ: 14.7952
Price-to-Sales TTM: 134.3508
IPO Date:
Fiscal Year End: September
Full Time Employees: 525
Back to stocks